美國政府今日通過兩種stem cell的使用申請，可供正式的計畫申請與公開販賣。
ESI-014和ESI-017為申請的六種細胞株中的其中兩株。
原始連結: http://www.biotechniques.com/news/biotechniquesNews/biotechniques-318290.html?utm_source=BioTechniques+Newsletters+%26+e-Alerts&utm_campaign=31ca546ffb-Daily_06032011&utm_medium=email
BioTime, Inc., a biotechnology company, has received NIH approval for two of
their six embryonic stem cell lines. Developed and derived under the
regulations of current Good Manufacturing Practices (cGMP), ESI-014 and
ESI-017 can now be used for human clinical applications, mainly in the areas
of tissue repair or replacement.
“The concept is that people will purchase these cells for a very reasonable price, use them for their research purposes, and have very good confidence that these lines have been thoroughly tested, sequenced, and documented,” says Walter Funk, Vice President of Stem Cell Research at BioTime.
BioTime has also submitted four other stem cell lines to the NIH for approval that are currently in review. Five out of the six cell lines, excluding ESI-014, have been completely sequenced at the genomic level. BioTime plans to release this data to researchers in a future publication to enable translation of the genetic composition of these cells to the commercial production of successful therapeutic products in regenerative medicine.
“We look forward in the future to having all of the six lines in the NIH registry, and we think that’s an important issue for researchers to be able to access a collection of these cell lines for research purposes,” says Funk.
留言列表
